Renalytix PLC
LSE:RENX

Watchlist Manager
Renalytix PLC Logo
Renalytix PLC
LSE:RENX
Watchlist
Price: 6 GBX -4%
Market Cap: 26.2m GBX
Section:
 

Relative Value

The Relative Value of one RENX stock under the Base Case scenario is hidden GBX. Compared to the current market price of 6 GBX, Renalytix PLC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RENX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

11.8
P/S
P/S
Price to Sales
11.8
vs History
95
vs Industry
8
Median 3Y
28.2
Median 5Y
100.8
Industry
2.3
Forward
0
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-7.1
Industry
22.5
Forward
-0
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-9.7
Industry
14.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-15.5
Industry
21.4
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-4.3
Median 5Y
21.8
Industry
2.2
More Details
285
EV/S
EV/S
Enterprise Value to Sales
285
vs History
20
vs Industry
Median 3Y
-19.2
Median 5Y
-341.8
Industry
2.5
Forward
0.5
More Details
712.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
712.6
vs History
20
vs Industry
Median 3Y
-206
Median 5Y
-1 088.1
Industry
5.2
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
53
Median 3Y
1.6
Median 5Y
21.2
Industry
11.9
Forward
-0.7
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
49
Median 3Y
1.4
Median 5Y
20
Industry
16.8
Forward
-0.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
52
Median 3Y
1.5
Median 5Y
27.3
Industry
14.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
42
Median 3Y
1.5
Median 5Y
27.2
Industry
18.6
More Details
77.7
EV/IC
EV/IC
Enterprise Value to IC
77.7
vs History
20
vs Industry
1
Median 3Y
13.9
Median 5Y
-28.5
Industry
1.9
More Details

Multiples Across Competitors

RENX Competitors Multiples
Renalytix PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Renalytix PLC
LSE:RENX
26.2m GBP 11.8 -1.7 -49.7 -49.7
US
Veeva Systems Inc
NYSE:VEEV
39.6B USD 12.9 46.1 35.5 37.1
US
Cerner Corp
LSE:0R00
31.3B USD 5.4 53.1 21.9 43.2
AU
Pro Medicus Ltd
ASX:PME
22B AUD 99.6 190.6 131.6 131.6
JP
M3 Inc
TSE:2413
1.5T JPY 4.4 31.9 16.2 19.9
US
Doximity Inc
NYSE:DOCS
8.2B USD 13.2 32.5 28.4 29.8
US
Waystar Holding Corp
NASDAQ:WAY
5.8B USD 5.6 52 17.3 27
SE
Sectra AB
STO:SECT B
45.5B SEK 20.3 70.4 -139 -139
IN
Inventurus Knowledge Solutions Ltd
NSE:IKS
283.6B INR 10.7 58.5 36.3 42.4
CN
Winning Health Technology Group Co Ltd
SZSE:300253
21B CNY 11 -77.6 -135 -135
US
Inspire Medical Systems Inc
NYSE:INSP
2.8B USD 3.1 61.9 49.4 66.4
P/E Multiple
Earnings Growth PEG
UK
Renalytix PLC
LSE:RENX
Average P/E: 66.3
Negative Multiple: -1.7 		N/A N/A
US
Veeva Systems Inc
NYSE:VEEV
46.1
32%
1.4
US
C
Cerner Corp
LSE:0R00
53.1
N/A N/A
AU
Pro Medicus Ltd
ASX:PME
190.6
32%
6
JP
M3 Inc
TSE:2413
31.9
16%
2
US
Doximity Inc
NYSE:DOCS
32.5
18%
1.8
US
W
Waystar Holding Corp
NASDAQ:WAY
52
N/A N/A
SE
Sectra AB
STO:SECT B
70.4
17%
4.1
IN
I
Inventurus Knowledge Solutions Ltd
NSE:IKS
58.5
31%
1.9
CN
Winning Health Technology Group Co Ltd
SZSE:300253
Negative Multiple: -77.6
92%
N/A
US
Inspire Medical Systems Inc
NYSE:INSP
61.9
13%
4.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Renalytix PLC
LSE:RENX
Average EV/EBITDA: 42.1
Negative Multiple: -49.7 		N/A N/A
US
Veeva Systems Inc
NYSE:VEEV
35.5
39%
0.9
US
C
Cerner Corp
LSE:0R00
21.9
N/A N/A
AU
Pro Medicus Ltd
ASX:PME
131.6
32%
4.1
JP
M3 Inc
TSE:2413
16.2
14%
1.2
US
Doximity Inc
NYSE:DOCS
28.4
23%
1.2
US
W
Waystar Holding Corp
NASDAQ:WAY
17.3
24%
0.7
SE
Sectra AB
STO:SECT B
Negative Multiple: -139 N/A N/A
IN
I
Inventurus Knowledge Solutions Ltd
NSE:IKS
36.3
24%
1.5
CN
Winning Health Technology Group Co Ltd
SZSE:300253
Negative Multiple: -135
36%
N/A
US
Inspire Medical Systems Inc
NYSE:INSP
49.4
85%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Renalytix PLC
LSE:RENX
Average EV/EBIT: 49.7
Negative Multiple: -49.7 		N/A N/A
US
Veeva Systems Inc
NYSE:VEEV
37.1
39%
1
US
C
Cerner Corp
LSE:0R00
43.2
N/A N/A
AU
Pro Medicus Ltd
ASX:PME
131.6
31%
4.2
JP
M3 Inc
TSE:2413
19.9
N/A N/A
US
Doximity Inc
NYSE:DOCS
29.8
25%
1.2
US
W
Waystar Holding Corp
NASDAQ:WAY
27
58%
0.5
SE
Sectra AB
STO:SECT B
Negative Multiple: -139 N/A N/A
IN
I
Inventurus Knowledge Solutions Ltd
NSE:IKS
42.4
26%
1.6
CN
Winning Health Technology Group Co Ltd
SZSE:300253
Negative Multiple: -135
47%
N/A
US
Inspire Medical Systems Inc
NYSE:INSP
66.4
34%
2

See Also

Summary
RENX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RENX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RENX stock valuation using valuation multiples.
Wall Street Estimates
RENX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RENX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 308,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.